NO20081636L - FAP - inhibitorer - Google Patents
FAP - inhibitorerInfo
- Publication number
- NO20081636L NO20081636L NO20081636A NO20081636A NO20081636L NO 20081636 L NO20081636 L NO 20081636L NO 20081636 A NO20081636 A NO 20081636A NO 20081636 A NO20081636 A NO 20081636A NO 20081636 L NO20081636 L NO 20081636L
- Authority
- NO
- Norway
- Prior art keywords
- fap inhibitors
- fap
- inhibitors
- cancer
- compounds
- Prior art date
Links
- 239000003112 inhibitor Substances 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 150000001875 compounds Chemical class 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/08—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hydrocarbon radicals, substituted by hetero atoms, attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D207/00—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D207/02—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom
- C07D207/04—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members
- C07D207/10—Heterocyclic compounds containing five-membered rings not condensed with other rings, with one nitrogen atom as the only ring hetero atom with only hydrogen or carbon atoms directly attached to the ring nitrogen atom having no double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D207/16—Carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/06—Antianaemics
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Hematology (AREA)
- Oncology (AREA)
- Diabetes (AREA)
- Dermatology (AREA)
- Communicable Diseases (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Pyrrole Compounds (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Hydrogenated Pyridines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US71332405P | 2005-09-02 | 2005-09-02 | |
| EP05108049A EP1760076A1 (en) | 2005-09-02 | 2005-09-02 | FAP Inhibitors |
| PCT/IB2006/003512 WO2007085895A2 (en) | 2005-09-02 | 2006-08-31 | Fap inhibitors |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| NO20081636L true NO20081636L (no) | 2008-05-29 |
Family
ID=38309561
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20081636A NO20081636L (no) | 2005-09-02 | 2008-04-02 | FAP - inhibitorer |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US8183280B2 (enExample) |
| EP (2) | EP1760076A1 (enExample) |
| JP (1) | JP2009507011A (enExample) |
| KR (1) | KR20080043383A (enExample) |
| AU (1) | AU2006336854A1 (enExample) |
| CA (1) | CA2627607A1 (enExample) |
| NO (1) | NO20081636L (enExample) |
| RU (1) | RU2008112683A (enExample) |
| WO (1) | WO2007085895A2 (enExample) |
| ZA (1) | ZA200802867B (enExample) |
Families Citing this family (55)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7407955B2 (en) | 2002-08-21 | 2008-08-05 | Boehringer Ingelheim Pharma Gmbh & Co., Kg | 8-[3-amino-piperidin-1-yl]-xanthines, the preparation thereof and their use as pharmaceutical compositions |
| US7501426B2 (en) | 2004-02-18 | 2009-03-10 | Boehringer Ingelheim International Gmbh | 8-[3-amino-piperidin-1-yl]-xanthines, their preparation and their use as pharmaceutical compositions |
| DE102004054054A1 (de) | 2004-11-05 | 2006-05-11 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | Verfahren zur Herstellung chiraler 8-(3-Amino-piperidin-1-yl)-xanthine |
| DE102005035891A1 (de) | 2005-07-30 | 2007-02-08 | Boehringer Ingelheim Pharma Gmbh & Co. Kg | 8-(3-Amino-piperidin-1-yl)-xanthine, deren Herstellung und deren Verwendung als Arzneimittel |
| SG174054A1 (en) | 2006-05-04 | 2011-09-29 | Boehringer Ingelheim Int | Polymorphs |
| PE20080251A1 (es) | 2006-05-04 | 2008-04-25 | Boehringer Ingelheim Int | Usos de inhibidores de dpp iv |
| EP1852108A1 (en) | 2006-05-04 | 2007-11-07 | Boehringer Ingelheim Pharma GmbH & Co.KG | DPP IV inhibitor formulations |
| US8933201B2 (en) | 2006-06-07 | 2015-01-13 | The Board Of Regents Of The University Of Oklahoma | Substrates and inhibitors of antiplasmin cleaving enzyme and fibroblast activation protein and methods of use |
| WO2009024542A2 (en) * | 2007-08-17 | 2009-02-26 | Boehringer Ingelheim International Gmbh | Purin derivatives for use in the treatment of fab-related diseases |
| EP2071337A1 (en) * | 2007-12-10 | 2009-06-17 | F.Hoffmann-La Roche Ag | Seprase as a marker for cancer |
| EP2223115B1 (en) * | 2007-12-10 | 2011-09-14 | Roche Diagnostics GmbH | Seprase as a marker for cancer |
| RU2494094C2 (ru) * | 2008-03-05 | 2013-09-27 | Нэшнл Хелт Рисерч Инститьютс | Производные пирролидина |
| AR071175A1 (es) | 2008-04-03 | 2010-06-02 | Boehringer Ingelheim Int | Composicion farmaceutica que comprende un inhibidor de la dipeptidil-peptidasa-4 (dpp4) y un farmaco acompanante |
| UY32030A (es) | 2008-08-06 | 2010-03-26 | Boehringer Ingelheim Int | "tratamiento para diabetes en pacientes inapropiados para terapia con metformina" |
| KR20190016601A (ko) | 2008-08-06 | 2019-02-18 | 베링거 인겔하임 인터내셔날 게엠베하 | 메트포르민 요법이 부적합한 환자에서의 당뇨병 치료 |
| KR20110067096A (ko) | 2008-09-10 | 2011-06-21 | 베링거 인겔하임 인터내셔날 게엠베하 | 당뇨병 및 관련 상태를 치료하기 위한 병용 요법 |
| AU2009296513A1 (en) * | 2008-09-25 | 2010-04-01 | Molecular Insight Pharmaceuticals, Inc. | Selective seprase inhibitors |
| US20200155558A1 (en) | 2018-11-20 | 2020-05-21 | Boehringer Ingelheim International Gmbh | Treatment for diabetes in patients with insufficient glycemic control despite therapy with an oral antidiabetic drug |
| EA022310B1 (ru) | 2008-12-23 | 2015-12-30 | Бёрингер Ингельхайм Интернациональ Гмбх | Солевые формы органического соединения |
| AR074990A1 (es) | 2009-01-07 | 2011-03-02 | Boehringer Ingelheim Int | Tratamiento de diabetes en pacientes con un control glucemico inadecuado a pesar de la terapia con metformina |
| EP2389176A4 (en) * | 2009-01-23 | 2012-08-01 | Univ Sydney | NEW THERAPY FOR METABOLISM DISEASE |
| BR112012012641A2 (pt) | 2009-11-27 | 2020-08-11 | Boehringer Ingelheim International Gmbh | TRATAMENTO DE PACIENTES DIABÉTICOS GENOTIPADOS COM INIBIDORES DE DPP-lVTAL COMO LINAGLIPTINA |
| KR101927068B1 (ko) | 2010-05-05 | 2018-12-10 | 베링거 인겔하임 인터내셔날 게엠베하 | 체중 감소 치료에 후속하는 dpp-4 억제제에 의한 순차적 병용 요법 |
| CA2803504C (en) | 2010-06-24 | 2022-08-30 | Boehringer Ingelheim International Gmbh | A combination for diabetes therapy comprising linagliptin and a long-acting insulin |
| WO2012061408A2 (en) * | 2010-11-02 | 2012-05-10 | Rigel Pharmaceuticals. Inc. | Method for making macrocycles |
| US9034883B2 (en) | 2010-11-15 | 2015-05-19 | Boehringer Ingelheim International Gmbh | Vasoprotective and cardioprotective antidiabetic therapy |
| AU2011340200B2 (en) * | 2010-12-06 | 2017-04-06 | The University Of British Columbia | Granzyme B inhibitor compositions, methods and uses for promoting wound healing |
| EP3517539B1 (en) | 2011-07-15 | 2022-12-14 | Boehringer Ingelheim International GmbH | Substituted dimeric quinazoline derivative, its preparation and its use in pharmaceutical compositions for the treatment of type i and ii diabetes |
| EP2804859B1 (en) | 2012-01-17 | 2019-06-12 | Universiteit Antwerpen | Novel fap inhibitors |
| US9555001B2 (en) | 2012-03-07 | 2017-01-31 | Boehringer Ingelheim International Gmbh | Pharmaceutical composition and uses thereof |
| EP4151218A1 (en) | 2012-05-14 | 2023-03-22 | Boehringer Ingelheim International GmbH | Linagliptin, a xanthine derivative as dpp-4 inhibitor, for use in the treatment of sirs and/or sepsis |
| JP6224084B2 (ja) | 2012-05-14 | 2017-11-01 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | 糸球体上皮細胞関連障害及び／又はネフローゼ症候群の治療に用いるｄｐｐ−４阻害薬としてのキサンチン誘導体 |
| WO2013174767A1 (en) | 2012-05-24 | 2013-11-28 | Boehringer Ingelheim International Gmbh | A xanthine derivative as dpp -4 inhibitor for use in modifying food intake and regulating food preference |
| JP2015526402A (ja) * | 2012-06-29 | 2015-09-10 | ジーイー・ヘルスケア・リミテッド | 線維症のイメージング |
| EA021236B1 (ru) * | 2012-10-03 | 2015-05-29 | Дафот Энтерпраизес Лимитед | Nα-АЦИЛЬНЫЕ ПРОИЗВОДНЫЕ АМИНОАЦИЛ-2-ЦИАНОПИРРОЛИДИНА - ИНГИБИТОРЫ ПРОЛИЛЭНДОПЕПТИДАЗЫ И ДИПЕПТИДИЛПЕПТИДАЗЫ-IV, ОБЛАДАЮЩИЕ ГИПОГЛИКЕМИЧЕСКИМ, ПРОТИВОГИПОКСИЧЕСКИМ, НЕЙРОПРОТЕКТОРНЫМ И УЛУЧШАЮЩИМ КОГНИТИВНЫЕ ФУНКЦИИ ДЕЙСТВИЕМ |
| EP2730571A1 (en) | 2012-11-12 | 2014-05-14 | Universitat De Barcelona | 1-[1-(benzoyl)-pyrrolidine-2-carbonyl]-pyrrolidine-2-carbonitrile derivatives |
| JP6615109B2 (ja) | 2014-02-28 | 2019-12-04 | ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング | Ｄｐｐ−４阻害薬の医学的使用 |
| JP2017516862A (ja) * | 2014-05-30 | 2017-06-22 | ブリティッシュ コロンビア キャンサー エージェンシー ブランチ | アンドロゲン受容体調節物質及びその使用方法 |
| WO2017211979A1 (en) | 2016-06-10 | 2017-12-14 | Boehringer Ingelheim International Gmbh | Combinations of linagliptin and metformin |
| US20200237936A1 (en) | 2016-12-14 | 2020-07-30 | Purdue Research Foundation | Fibroblast activation protein (fap)-targeted imaging and therapy |
| MA47215A (fr) | 2017-01-09 | 2019-11-13 | Bioxcel Therapeutics Inc | Procédés prédictifs et diagnostiques pour le cancer de la prostate |
| SG11202005563YA (en) * | 2017-12-15 | 2020-07-29 | Praxis Biotech LLC | Inhibitors of fibroblast activation protein |
| JP2022514352A (ja) | 2018-12-21 | 2022-02-10 | プラクシス バイオテック エルエルシー | 線維芽細胞活性化タンパク質の阻害剤 |
| KR102274077B1 (ko) * | 2019-03-29 | 2021-07-09 | 보령제약 주식회사 | Fap 저해제로서의 피롤리딘 유도체 및 이를 포함하는 약학적 조성물 |
| KR102799014B1 (ko) | 2019-11-06 | 2025-04-28 | 주식회사유한양행 | 피롤리딘 및 피페리딘 화합물 |
| MX2022011842A (es) * | 2020-03-24 | 2022-10-20 | Tufts College | Agentes de imagen y radiofarmacos dirigidos a fap, y usos relacionados con los mismos. |
| JP2023525082A (ja) | 2020-05-07 | 2023-06-14 | アンスティテュ・クリー | 免疫抑制線維芽細胞集団のバイオマーカーとしてのａｎｔｘｒ１及び免疫療法に対する応答を予測するためのその使用 |
| UY39569A (es) * | 2020-12-17 | 2022-07-29 | Astrazeneca Ab | N-(2-(4-cianotiazolidin-3-il)-2-oxoetil)- quinolin-4-carboxamidas |
| AU2022306289A1 (en) | 2021-07-09 | 2024-01-18 | Aligos Therapeutics, Inc. | Anti-viral compounds |
| WO2023043816A1 (en) | 2021-09-17 | 2023-03-23 | Aligos Therapeutics, Inc. | Anti-viral compounds for treating coronavirus, picornavirus, and norovirus infections |
| MA71235A (fr) * | 2022-06-21 | 2025-04-30 | Astrazeneca Ab | N-(2-(3-cyano-2-azabicyclo[3.1.0]hexan-2-yl)-2-oxoéthyl)- quinoléine-4-carboxamidess |
| EP4543878A1 (en) * | 2022-06-21 | 2025-04-30 | Astrazeneca AB | N-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- quinoline-4-carboxamides |
| AU2023288645A1 (en) * | 2022-06-21 | 2025-02-13 | Astrazeneca Ab | Solid-state forms of n-(2-(4-cyanothiazolidin-3-yl)-2-oxoethyl)- 6-morpholinoquinoline-4-carboxamide |
| WO2025046043A1 (en) | 2023-08-31 | 2025-03-06 | Stichting Radboud Universitair Medisch Centrum | Endometriosis tracer |
| CN118955616B (zh) * | 2024-05-01 | 2025-09-02 | 杭州景嘉航生物医药科技有限公司 | 一种靶向结合成纤维细胞活化蛋白化合物及应用 |
Family Cites Families (39)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3017929A (en) * | 1959-01-07 | 1962-01-23 | Beloit Iron Works | Head box with balanced slice body |
| US4873342A (en) * | 1985-04-16 | 1989-10-10 | Suntory Limited | Dipeptide derivative and synthesis and use thereof |
| CA1320734C (en) * | 1986-02-04 | 1993-07-27 | Suntory Limited | Pyrrolidineamide derivative of acylamino acid and pharmaceutical composition containing the same |
| JPH0774193B2 (ja) | 1986-07-29 | 1995-08-09 | サントリー株式会社 | ジペプチド誘導体及びその製法並びに用途 |
| DE3855875T2 (de) | 1987-02-23 | 1997-08-28 | Ono Pharmaceutical Co | Thiazolidin-Derivate |
| CA2004028C (en) * | 1988-12-08 | 1998-09-22 | Motoki Torizuka | Condensed benzene derivative |
| WO1990012005A1 (fr) * | 1989-04-13 | 1990-10-18 | Japan Tobacco Inc. | Nouveaux derives aminoacides possedant une activite d'inhibiteur de la prolylendopeptidase |
| US5462928A (en) * | 1990-04-14 | 1995-10-31 | New England Medical Center Hospitals, Inc. | Inhibitors of dipeptidyl-aminopeptidase type IV |
| EP0536399B1 (en) * | 1990-06-07 | 1996-01-24 | Zeria Pharmaceutical Co., Ltd. | Novel arylalkanoylamine derivative and drug containing the same |
| FR2681864B1 (fr) * | 1991-09-27 | 1995-03-31 | Adir | Nouveaux derives bicycliques azotes, leur procede de preparation et les compositions pharmaceutiques qui les contiennent. |
| ES2148229T3 (es) * | 1992-05-20 | 2000-10-16 | Merck & Co Inc | Eteres y tioeteres en la posicion 17 de 4-aza-esteroides. |
| EP0670309A1 (en) | 1992-11-20 | 1995-09-06 | Japan Tobacco Inc. | Compound with prolyl endopeptidase inhibitor activity and pharmaceutical use thereof |
| JP3810097B2 (ja) * | 1993-01-15 | 2006-08-16 | 明治製菓株式会社 | ピロリジン−２−イルカルボニル複素環式化合物誘導体 |
| WO1995003277A1 (en) | 1993-07-23 | 1995-02-02 | Zaidan Hojin Biseibutsu Kagaku Kenkyukai | Novel pyrrolidine derivative |
| JPH07126229A (ja) * | 1993-11-02 | 1995-05-16 | Yoshitomi Pharmaceut Ind Ltd | ジアリールケトン化合物およびその医薬用途 |
| CZ134296A3 (en) | 1993-11-09 | 1996-12-11 | Merck & Co Inc | Piperidine, pyrrolidine and hexahydro-1h-azepine derivatives, process of their preparation and pharmaceutical compositions containing thereof |
| US5494919A (en) * | 1993-11-09 | 1996-02-27 | Merck & Co., Inc. | 2-substituted piperidines, pyrrolidines and hexahydro-1H-azepines promote release of growth hormone |
| JPH07228529A (ja) * | 1994-02-17 | 1995-08-29 | Zeria Pharmaceut Co Ltd | コリンエステラーゼ賦活剤 |
| US5574017A (en) * | 1994-07-05 | 1996-11-12 | Gutheil; William G. | Antibacterial agents |
| US6017887A (en) | 1995-01-06 | 2000-01-25 | Sibia Neurosciences, Inc. | Peptide, peptide analog and amino acid analog protease inhibitors |
| PT832065E (pt) * | 1995-06-06 | 2002-02-28 | Pfizer | N-(indole-2-carbonil)-glicinamidas e seus derivados como agentes antidiabeticos |
| WO2000010549A1 (en) | 1998-08-21 | 2000-03-02 | Point Therapeutics, Inc. | Regulation of substrate activity |
| CN1362947A (zh) | 1999-03-15 | 2002-08-07 | Axys药物公司 | 用作蛋白酶抑制剂的n－氰基甲基酰胺 |
| WO2001034594A1 (en) * | 1999-11-12 | 2001-05-17 | Guilford Pharmaceuticals, Inc. | Dipeptidyl peptidase iv inhibitors and methods of making and using dipeptidyl peptidase iv inhibitors |
| GB9928330D0 (en) * | 1999-11-30 | 2000-01-26 | Ferring Bv | Novel antidiabetic agents |
| JP2003520849A (ja) | 2000-01-24 | 2003-07-08 | ノボ ノルディスク アクティーゼルスカブ | 酵素ｄｐｐ−ｉｖの阻害剤であるｎ−置換２−シアノピロールおよび−ピロリン |
| GB0010188D0 (en) * | 2000-04-26 | 2000-06-14 | Ferring Bv | Inhibitors of dipeptidyl peptidase IV |
| NZ524974A (en) | 2000-10-06 | 2005-10-28 | Tanabe Seiyaku Co | Aliphatic nitrogen-containing 5-membered ring compound |
| WO2002079146A2 (en) | 2001-03-02 | 2002-10-10 | Bristol-Myers Squibb Company | Compounds useful as modulators of melanocortin receptors and pharmaceutical compositions comprising same |
| FR2822826B1 (fr) | 2001-03-28 | 2003-05-09 | Servier Lab | Nouveaux derives sulfonyles d'alpha-amino-acides, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
| GB0115517D0 (en) | 2001-06-25 | 2001-08-15 | Ferring Bv | Novel antidiabetic agents |
| EP1399471B1 (en) * | 2001-06-27 | 2008-01-30 | Probiodrug AG | Use of dipeptidyl peptidase iv inhibitors as therapeutics for neurological disorders |
| FI20011466A0 (fi) * | 2001-07-04 | 2001-07-04 | Orion Corp | Prolyylioligopeptidaasia inhiboivaa aktiivisuutta omaavia yhdisteitä, niiden valmistusmenetelmiä ja käyttö |
| EP1492525A2 (en) * | 2001-08-16 | 2005-01-05 | Probiodrug AG | Use of inhibitors of proline endopeptidase to modulate inositol (1,4,5) triphosphate concentration dependent on intracellular signal cascades |
| WO2003084940A1 (en) * | 2002-04-08 | 2003-10-16 | Alangudi Sankaranarayanan | Thiazolidine-4-carbonitriles and analogues and their use as dipeptidyl-peptidas inhibitors |
| JP2005531540A (ja) * | 2002-04-30 | 2005-10-20 | トラスティーズ・オブ・タフツ・カレッジ | セリンプロテアーゼ阻害剤のスマートプロドラッグ |
| JP2006507352A (ja) | 2002-07-09 | 2006-03-02 | ポイント セラピューティクス， インコーポレイテッド | イソロイシンのボロプロリン化合物に関する方法および組成物 |
| KR100732440B1 (ko) * | 2002-08-30 | 2007-06-27 | 에자이 알앤드디 매니지먼트 가부시키가이샤 | 질소 함유 방향환 유도체 |
| WO2007005991A1 (en) * | 2005-07-05 | 2007-01-11 | Trustees Of Tufts College | Inhibitors of fibroblast activation protein alpha |
-
2005
- 2005-09-02 EP EP05108049A patent/EP1760076A1/en not_active Withdrawn
-
2006
- 2006-08-31 EP EP06849433A patent/EP1919864A2/en not_active Withdrawn
- 2006-08-31 KR KR1020087007975A patent/KR20080043383A/ko not_active Withdrawn
- 2006-08-31 JP JP2008528601A patent/JP2009507011A/ja active Pending
- 2006-08-31 US US11/991,286 patent/US8183280B2/en not_active Expired - Fee Related
- 2006-08-31 RU RU2008112683/04A patent/RU2008112683A/ru not_active Application Discontinuation
- 2006-08-31 AU AU2006336854A patent/AU2006336854A1/en not_active Abandoned
- 2006-08-31 CA CA002627607A patent/CA2627607A1/en not_active Abandoned
- 2006-08-31 WO PCT/IB2006/003512 patent/WO2007085895A2/en not_active Ceased
-
2008
- 2008-04-01 ZA ZA200802867A patent/ZA200802867B/xx unknown
- 2008-04-02 NO NO20081636A patent/NO20081636L/no not_active Application Discontinuation
Also Published As
| Publication number | Publication date |
|---|---|
| EP1919864A2 (en) | 2008-05-14 |
| EP1760076A1 (en) | 2007-03-07 |
| AU2006336854A1 (en) | 2007-08-02 |
| CA2627607A1 (en) | 2007-08-02 |
| WO2007085895A3 (en) | 2008-04-17 |
| RU2008112683A (ru) | 2009-10-20 |
| ZA200802867B (en) | 2008-12-31 |
| WO2007085895A2 (en) | 2007-08-02 |
| JP2009507011A (ja) | 2009-02-19 |
| US20100081701A1 (en) | 2010-04-01 |
| US8183280B2 (en) | 2012-05-22 |
| KR20080043383A (ko) | 2008-05-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO20081636L (no) | FAP - inhibitorer | |
| NO20065148L (no) | Monocykliske heterocykler som kinase inhibitorer | |
| NO20082594L (no) | Pyrimidinylbenzotiofenforbindelser | |
| NO20070933L (no) | Indazoler anvendbare i behandling av kardiovaskulaere sykdommer | |
| NO20071127L (no) | Triazoloftalaziner | |
| EA200701396A1 (ru) | Триазолофталазины в качестве ингибиторов pde-2 | |
| EA200801291A1 (ru) | Карбониламинопирролопиразолы в качестве эффективных ингибиторов киназ | |
| EA201070247A1 (ru) | Ингибиторы протеасом | |
| CY1109911T1 (el) | Πυρρολοβενζοδιαζεπινες | |
| EA200971051A1 (ru) | Ингибиторы p70 s6 киназы | |
| EA201170052A1 (ru) | Производные тиофена или тиазола и их применение как ингибиторов pi3k | |
| EA201270535A1 (ru) | Пуриновые производные, применимые в качестве ингибиторов hsp90 | |
| EA201170832A1 (ru) | Пуриновые соединения | |
| EA200900798A1 (ru) | Производные индол-4-илпиримидинил-2-иламина и их применение в качестве ингибиторов циклинзависимой киназы | |
| CY1110900T1 (el) | Χημικες ενωσεις | |
| CY1108275T1 (el) | Χημικες ενωσεις | |
| NO20081454L (no) | Met-kinaseinhibitorer | |
| NO20072092L (no) | Sulfonamidforbindelser | |
| DK1761520T3 (da) | Kinaseinhibitorer | |
| EA200501928A1 (ru) | Пирролодигидроизохинолины как ингибиторы pde10 | |
| EA201200323A1 (ru) | Соединения и композиции, как ингибиторы протеинкиназы | |
| EA201170531A1 (ru) | Соединения на основе пиридина и пиримидина в качестве ингибиторов сигнального пути wnt для лечения рака | |
| EA200801428A1 (ru) | Производные пиридиазинона для лечения опухолей | |
| CL2007002384A1 (es) | Uso de compuestos derivados de 2,5-dihidroxibenceno para el tratamiento de la psoriasis. | |
| EA201170680A1 (ru) | Ингибиторы акт и p70 s6-киназы |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FC2A | Withdrawal, rejection or dismissal of laid open patent application |